SARS-CoV-2 (COVID-19) Spike S2 Antibody [4F10]

Contact us
ProSci
Product Code: PSI-PM-9428
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-PM-9428-0.02mg0.02mg£150.00
Quantity:
PSI-PM-9428-0.1mg0.1mg£515.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: 4F10
Regulatory Status: RUO
Target Species: Virus
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunofluorescence (IF)
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Shipping:
blue ice or RT
Storage:
SARS-CoV-2 (COVID-19) Spike S2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 4
<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (PM-9428, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong spike protein signal was observed in macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.
2 / 4
<strong>Figure 2 Overexpression Validation in Spike Transfected 293 Cells </strong><br> Loading: 5 ug per lane of 293 cell lysate. Antibodies: SARS-CoV-2 (COVID-19) Spike S2, PM-9428, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10,000 dilution. Lane 1: 0.5 μg/mL and Lane 2: 1 μg/mL
3 / 4
<strong>Figure 3 Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Spike in 293T Cells</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed 293T cells labeling SARS-CoV-2 (COVID-19) Spike S2 with PM-9428 at 20 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).
4 / 4
<strong>Figure 4 ELISA Test</strong><br> Antibodies: SARS-CoV-2 (COVID-19) Spike S2 antibody, PM-9428 (1 μg/mL). A direct ELISA was performed using immunogen or control peptide as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike antibody as the capture antibody. Secondary: Goat anti-mouse IgG HRP conjugate at 1:5,000 dilution. Detection range is from 0.3 ng/mL to 1,000 ng/mL.
❮❯

<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (PM-9428, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong spike protein signal was observed in macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.
<strong>Figure 2 Overexpression Validation in Spike Transfected 293 Cells </strong><br> Loading: 5 ug per lane of 293 cell lysate. Antibodies: SARS-CoV-2 (COVID-19) Spike S2, PM-9428, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10,000 dilution. Lane 1: 0.5 μg/mL and Lane 2: 1 μg/mL
<strong>Figure 3 Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Spike in 293T Cells</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed 293T cells labeling SARS-CoV-2 (COVID-19) Spike S2 with PM-9428 at 20 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).
<strong>Figure 4 ELISA Test</strong><br> Antibodies: SARS-CoV-2 (COVID-19) Spike S2 antibody, PM-9428 (1 μg/mL). A direct ELISA was performed using immunogen or control peptide as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike antibody as the capture antibody. Secondary: Goat anti-mouse IgG HRP conjugate at 1:5,000 dilution. Detection range is from 0.3 ng/mL to 1,000 ng/mL.

Documents

Further Information

Additional Names:
SARS-CoV-2 (COVID-19) Spike S2 Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein
Application Note:
WB: 1 μg/mL; IF: 20 μg/mL. IHC: 0.5 μg/mL

Antibody validated: Immunofluorescence and Western blot in human samples. Immunohisochemistry in COVID-19 patient samples. SARS-CoV-2 (COVID-19) Spike S2 antibody can be used for the detection of SARS-CoV-2 (COVID-19) Spike full length protein in ELISA. It will detect 4 ng of free peptide at 1 μg/mL. PM-9428 cannot be used for detection of SARS-CoV-2/SARS-CoV Spike S1, Spike ECD, Spike S2 ECD proteins. ) All other applications and species not yet tested.
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019?20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).
Background References:
  • Gorbalenya. bioRxiv: 2020.
  • Hui et al. Int J Infect Dis. 2020;91:264-266.
  • Belouzard et al. Viruses. 2012;4(6):1011-33.
  • Lee et al. J Virol. 2006;80(8):4079-87.
  • Wan et al. J Virol. 2020.
  • Wrapp et al. Science. 2020.
Buffer:
SARS-CoV-2 (COVID-19) Spike Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (100%)
Immunogen:
Anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (PM-9428) was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein.

The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Spike protein.
ISOFORMS:
SARS-CoV-2 (COVID-19) Spike has one isoform (1273aa).
NCBI Gene ID #:
43740568
NCBI Official Name:
surface glycoprotein
NCBI Official Symbol:
S
NCBI Organism:
Wuhan seafood market pneumonia virus
Physical State:
Liquid
Protein Accession #:
QHD43416
Protein GI Number:
1791269090
Purification:
SARS-CoV-2 (COVID-19) Spike Antibody is Protein G purified.
Research Area:
Infectious Disease,COVID-19
Swissprot #:
P0DTC2
User NOte:
Optimal dilutions for each application to be determined by the researcher.